The RNASE3 antibody targets the human RNASE3 protein, also known as eosinophil cationic protein (ECP), encoded by the RNASE3 gene. RNASE3 is a secreted enzyme predominantly expressed by eosinophils, a type of immune cell involved in inflammatory and allergic responses. It exhibits ribonuclease activity and plays a role in host defense against pathogens, particularly parasites, by disrupting microbial membranes. Elevated RNASE3 levels are associated with eosinophil activation in conditions like asthma, allergies, and certain parasitic infections, making it a biomarker for eosinophil-related pathologies.
Antibodies against RNASE3 are valuable tools for research and diagnostics. They enable detection and quantification of RNASE3 in biological samples (e.g., blood, tissues) to study eosinophil activity in diseases or assess therapeutic responses. Polyclonal and monoclonal RNASE3 antibodies are used in techniques like ELISA, Western blotting, and immunohistochemistry. Some therapeutic strategies also explore RNASE3-targeting antibodies to modulate eosinophil-mediated inflammation in chronic inflammatory disorders. However, the protein's cytotoxic properties and complex role in both protective immunity and tissue damage necessitate careful interpretation of antibody-based findings. Research continues to clarify RNASE3's dual functions and refine antibody applications in clinical contexts.